Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Ensysce Biosciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −3 vs. Q3 2023
- Shares held
- 53.1K
- −114.6K (−68.3%) vs. Q3 2023
- Total value
- $56.4K
- −$174.7K (−75.6%) vs. Q3 2023
- New holders
- 2
- 3 more added
- Sold out
- 5
- 2 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $832.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 18,175 | $19.3K | 0.00% | +2,756+17.9% | Added |
| Geode Capital Management, LLC | 16,281 | $17.0K | 0.00% | −149−0.9% | Reduced |
| Renaissance Technologies LLC | 10,957 | $12.0K | 0.00% | +10,957 | New |
| Tower Research Capital LLC (TRC) | 6,307 | $6.68K | 0.00% | +2,381+60.6% | Added |
| BlackRock Inc. | 975 | $1.03K | 0.00% | 00.0% | Unchanged |
| Advisory Services Network, LLC | 347 | $368 | 0.00% | +347 | New |
| Wells Fargo & Company | 24 | $25 | 0.00% | +3+14.3% | Added |
| Plante Moran Financial Advisors, LLC | 20 | $21 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $3 | 0.00% | −144−98.0% | Reduced |
| Sabby Management, LLC | 0 | $0 | 0.00% | −96,973−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −19,113−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −14,616−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −59−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |